← Back to patent-cliff list
TY-0540
Tier C — Watch / tradeTY-0540
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK2, CDK4, CDK6
Indications (approved)：Castration-resistant prostate cancer, Breast cancer, HR阳性乳腺癌, Solid tumour, Metastatic cancer, Neoplasm
Regional status
US
Phase I
2023-06-22
EU
-
China
Phase II
2024-01-02
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TY-0540?
Approved indications include: Castration-resistant prostate cancer, Breast cancer, HR阳性乳腺癌, Solid tumour, Metastatic cancer, Neoplasm.
When does the TY-0540 patent expire?
No public expiry year is available for TY-0540 yet; this page updates once verified.
How do I get a quote for TY-0540 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02